Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience.
about
Relationship between sialic acid and metabolic variables in Indian type 2 diabetic patientsAge and kidney function are the primary correlates of fasting plasma total homocysteine levels in non-diabetic and diabetic adults. Results from the 1999-2002 National Health and Nutrition Examination SurveyEmerging drugs in peripheral arterial diseaseDiabetes mellitus is associated with shortened activated partial thromboplastin time and increased fibrinogen valuesSex differences in cardiovascular disease - Impact on care and outcomes.Fibrinogen in relation to personal history of prevalent hypertension, diabetes, stroke, intermittent claudication, coronary heart disease, and family history: the Scottish Heart Health StudyImpaired modulation of circadian rhythms in patients with diabetes mellitus: a risk factor for cardiac thrombotic events?Non-insulin-dependent (type II) diabetes mellitus.Evidence of left ventricular dysfunction in asymptomatic elderly patients with non-insulin-dependent diabetes mellitus.Proteomic analysis in type 2 diabetes patients before and after a very low calorie diet reveals potential disease state and intervention specific biomarkers.Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study).Target organ damage and cardiovascular complications in patients with hypertension and type 2 diabetes in Spain: a cross-sectional study.Platelet function in patients with diabetes mellitus: from a theoretical to a practical perspectiveFibrinogen: biochemistry, epidemiology and determinants.The prevalence of peripheral arterial disease in korean patients with type 2 diabetes mellitus attending a university hospital.Prognostic relations between inflammatory markers and mortality in diabetic patients with non-ST elevation acute coronary syndrome.Duration of diabetes and risk of ischemic stroke: the Northern Manhattan StudyInsulin resistance in patients with polycystic ovary syndrome.Long-term clinical benefits of a platelet glycoprotein IIb/IIIa receptor blocker, abciximab (ReoPro), in high-risk diabetic patients undergoing percutaneous coronary intervention.4G/5G polymorphism of PAI-1 gene and Alu-repeat I/D polymorphism of TPA gene in Turkish patients with polycystic ovary syndrome.Pathobiology and cell interactions of platelets in diabetes.Comorbidities Associated with Obstructive Sleep Apnea: a Retrospective Study.Major adverse cardiovascular events with basal insulin peglispro versus comparator insulins in patients with type 1 or type 2 diabetes: a meta-analysis.Value of exercise tolerance testing in evaluation of diabetic patients presented with atypical chest discomfort.Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone.Relationship between plasma sialic acid and fibrinogen concentration and incident micro- and macrovascular complications in type 1 diabetes. The EURODIAB Prospective Complications Study (PCS)Changes in inflammatory biomarkers across weight classes in a representative US population: a link between obesity and inflammationCardiovascular-renal complications and the possible role of plasminogen activator inhibitor: a review.The prognostic value of blood glucose level on admission in non-diabetic patients with acute myocardial infarction.Modeling metabolic homeostasis and nutrient sensing in Drosophila: implications for aging and metabolic diseasesEvaluation of serum fibrinogen, plasminogen, α2-anti-plasmin, and plasminogen activator inhibitor levels (PAI) and their correlation with presence of retinopathy in patients with type 1 DM.Adaptive Upregulation of Clumping Factor A (ClfA) by Staphylococcus aureus in the Obese, Type 2 Diabetic Host Mediates Increased Virulence.Fibrinogen: its emerging role as a cardiovascular risk factor.Fibrinogen: an important risk factor for atherothrombotic diseases.Hyperglycemia-induced production of acute phase reactants in adipose tissue.The role of haematological factors in diabetic peripheral arterial disease: the Edinburgh artery study.Gene expression changes in human islets exposed to type 1 diabetic serum.Response: the prevalence of peripheral arterial disease in korean patients with type 2 diabetes mellitus attending a university hospital (diabetes metab j 2011;35:543-50).The Diagnostic Value of Tc-99m MIBI Gated Myocardial Perfusion SPECT in Detection of Silent Myocardial Ischemia in Asymptomatic Patients with Type 2 Diabetes Mellitus.Differential effects of somatostatin on circulating tissue factor procoagulant activity and protein.
P2860
Q24812441-C3D44709-7513-4000-8595-33AF8F9B14E5Q24814535-B2AD16BD-4AE5-407C-8217-EA24A4101EB6Q28195408-33990359-A52C-45CD-9C19-B6C2ADD5B6E2Q28743200-783ED7BF-D123-4609-B387-903CE313FB69Q30234726-EA63EC9F-4E19-4A35-B8F9-D92F8EA08F50Q33612628-EAD681F9-8D0D-4025-8FFA-866E5E64A13EQ34180071-5BF8CFC8-8E03-4245-9DA4-7CFB71F3E16EQ34274596-B4E0F067-D8F8-4D53-B625-1BF6DBA76CCAQ34349703-93DCCE8B-E05B-48B4-9ED3-D89F3F887A7FQ34557152-BD74D1E2-03B1-48C2-B1B5-5A844EC58CA1Q34774079-6D511255-2439-4BF1-9C21-3194A198E692Q35129591-BAC7C836-DABB-4B09-AFB3-201D0F040928Q35174193-33A96913-6DBE-4E76-A51E-98BE08E8350DQ35538771-60D36FEA-7A2A-406C-8FE1-BFFABB280281Q35564091-622EDE5D-7756-480A-8D6C-8FBA195E2342Q35582120-C467936D-D076-42C0-B6D9-708F710E16F1Q35911582-F8B86EF6-FAF5-455A-857E-8B28D2919E89Q35932352-430803D5-CCC9-44C0-873D-498D3A427F11Q35937178-CD5E09CE-FF6F-4CAD-B6BF-F2CD907D8567Q36268407-D4B26611-8686-4EAF-8F59-69586ABF07FAQ36320564-5FCFCFC5-40BB-48D9-A101-7420854758F2Q36808834-472EC319-3F7D-4517-8303-600B4CA55EE5Q36907339-05BC3196-FF00-4678-A116-DE1E42ED5445Q36957436-3941F6AB-6663-4135-8BD5-9954A9A58BBBQ37154802-A71263DE-8049-4162-855A-EF14181659B9Q37157478-CAC47B9E-4C4F-47C5-9276-C9CA2DB29708Q37220941-CDF2D952-6E35-4443-ADF2-0D2D42BA8C8CQ37284133-B9BDA3E7-4009-42AF-8C04-DFEF81630AA2Q37314571-7643F9AA-7ED2-428E-B7C3-7086D85F55F0Q37621075-F0AF615B-CA03-4D86-B7D0-851A1CF149A0Q37730636-ADC58115-BCA2-4D4C-A954-4B289D6CAFE4Q40287232-81855B6D-D04A-4E75-8C5C-607ECB39073EQ40725303-A61AE198-9FFE-4B24-B420-2E813FF71194Q40744822-6A4E7EAE-B8C9-4D0A-B9A6-2B2A6B2C5405Q40781707-13CEC482-6326-4BAA-84FC-1D4AC76FADCAQ40811005-133FEAED-4D4C-477A-948E-AFB1493B8276Q41197312-91A3CA2B-92A2-43FA-A0C1-F20D0347C46AQ41386031-42531EC7-705D-4D27-B8A2-B7DE65AA8516Q41864421-BEDF7845-5451-4067-A8A6-B1481C1E3BE9Q42506566-7185DE3C-5D12-452A-BE4E-FC46B51101A9
P2860
Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience.
description
1990 nî lūn-bûn
@nan
1990年の論文
@ja
1990年学术文章
@wuu
1990年学术文章
@zh
1990年学术文章
@zh-cn
1990年学术文章
@zh-hans
1990年学术文章
@zh-my
1990年学术文章
@zh-sg
1990年學術文章
@yue
1990年學術文章
@zh-hant
name
Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience.
@en
Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience.
@nl
type
label
Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience.
@en
Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience.
@nl
prefLabel
Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience.
@en
Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience.
@nl
P2093
P1476
Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience.
@en
P2093
Belanger AJ
D'Agostino RB
P304
P356
10.1016/0002-8703(90)90026-T
P407
P577
1990-09-01T00:00:00Z